Improving the performance of rapid tests through clear instructions
Researchers at the RI-MUHC investigate whether rapid antigenic detection tests for COVID-19 could be adequately used in the workplace.
Five RI-MUHC researchers receive new funding from MI4
Cutting-edge projects in infection and immunity supported in Round 4 of MI4’s Seed Fund Grant program
Immunotherapy showing significant advancements in lung cancer treatment
Phase 3 clinical trial of neoadjuvant nivolumab leads to practice-changing results
The unexpected role of chloride channels in a rare neurological disorder
A new study finds mutations affecting the chloride channel of a glutamate transport protein in a rare disorder...
Where immune cells are located is critical for cancer immune therapy, a new study shows
An innovative new approach highlights the relevance of immune cells’ position within melanoma to inform on a...
TB and COVID-19, a joint battle?
On World TB Day 2022, we are looking at how researchers from the McGill International TB Centre at the RI-MUHC are working to raise awareness and to put an end to TB.
RI-MUHC team receives Discovery of the Year Award from Québec Science magazine
Jean-Jacques Lebrun’s team at the RI-MUHC has won the 2021 Québec Science Discovery of the Year Award...
Cecilia Costiniuk receives 2022 CAHR-CANFAR Excellence in Research Award
RI-MUHC researcher is committed to improving the lives of those living with HIV
RI-MUHC trainee honoured by the American Association for Cancer Research
Yasmine Benslimane is investigating how the female hormone estrogen influences the spread of colon cancer...
LSD, a future antianxiety pill?
A new study by Dr. Gabriella Gobbi reveals the neurobiological mechanisms by which LSD could relieve anxiety